GUIDELINES & PROTOCOLS

ADVISORY COMMITTEE

Osteoarthritis in Peripheral Joints – Diagnosis and Treatment

Effective Date: September 15, 2008

Scope

This guideline summarizes current recommendations for assessment, diagnosis and treatment of osteoarthritis (OA) in peripheral joints for patients 19 years-of-age and older. Discussion will include patient education, rehabilitation, medications, and surgical choices as viewed within the chronic disease management context. A medication table is enclosed for reference.

Diagnostic Code: 715 (Osteoarthritis)

Introduction

Arthritis is a leading cause of long-term disability and one of the leading economic burdens to society. From a 2005 survey, 10.8% of British Columbians aged 12-64 and 42.4% aged 65 and over self-report that they have arthritis or rheumatism.¹ OA is the most common form of arthritis. From British Columbia 2005/2006 Medical Services Plan (MSP) claims data (physician billing, hospitalizations and PharmaCare claims), approximately 306,000 people (6.03% of the population) received medical services for OA.²

OA should not be considered simple wear and tear of joints. It is a slowly progressing disorder of unknown cause, but risk factors include: obesity, muscle weakness, heavy physical activity, inactivity, previous trauma, reduced proprioception, family history³ of primary generalized OA, and mechanical factors. Often there is a progressive loss of articular cartilage and abnormal bone formation. OA symptoms usually begin in mature adults, presenting with minimal morning stiffness or stiffness after inactivity, pain in and around the affected joints (particularly with weight-bearing exercise), and transient pain alleviated with inactivity and rest. The joints usually have bony enlargement, crepitus with motion, and/or limitation of motion. Inflammation is usually absent or very mild. Any joint may be affected but most often involve the hands, great toes, spine, knees and hips.

Because there is no known cure for OA, the treatment goals are to: reduce pain, maintain or improve joint mobility, limit functional disability and improve self-management. The four pillars of treatment are: patient education, rehabilitation, medications and referrals (surgery and non-surgical). These are best achieved using a multidisciplinary approach and multi-modal treatments.





RECOMMENDATION 1 Follow an organized approach to achieve an accurate diagnosis and functional assessment

OA is a clinical diagnosis. There are no tests that are completely reliable in making the diagnosis. Current tests are primarily used to monitor the disease or exclude other types of arthritis. Radiographs may indicate OA but may not relate to symptoms. People with symptoms of osteoarthritis are usually mature adults and the elderly. As the patient is being considered for OA, it is recommended that assessment include the following:

- A. Patient History
- B. Physical Examination
- C. Assessment to Exclude Other Diagnoses
- D. Investigations
- E. Clinical Impression and Factors to Consider Prior to Treatment and Management

A. Patient History

FACTORS SUGGESTIVE OF OA (REFER TO APPENDIX A: HISTORY)	
 Gradual onset Absence of inflammation (morning stiffness < 30 minutes, minimal heat, minimal swelling, no redness) Absence of systemic symptoms or signs suggesting alternate diagnoses (Red Flags in Appendix C) 	 Joint pain with activity Joints most likely affected: hip, knee, cervical and lumbar spine, thumb CMC (Carpo-Metacarpal), finger PIP (Proximal Interphalangeal), DIP (Distal Interphalangeal), and first MTP (Metatarsophalangeal) joint
RISK FACTORS FOR DISEASE	
Older ageFamily history of generalized OAHeavy physical activity	ObesityPrevious trauma or deformity
COMORBIDITIES TO CONSIDER IN TREATMENT	
 GI (ulcers, bleeds and hepatic disease) Cardiovascular (hypertension, ischemic heart disease, stroke, CHF) Hepatic disease 	Renal impairmentAsthma (ASA and NSAIDs require caution)Depression
OTHER FACTORS TO CONSIDER IN TREATMENT	
 Cognitive status (ability to learn and to adhere to treatment) Substance abuse and/or prior dependency 	 Drug interactions (alcohol, OTC medications, supplements and herbals) Language issues (understand treatment recommendations)
HOW CONDITION IMPACTS PAIN AND FUNCTION	
 Sleep (night pain) Activities of daily living (ADLs/IADLs) Walking distance Others: falls, social isolation, depression 	 Recreation Pain features and level Work (household, paid employment, volunteer activities)

B. Physical Examination (For more detailed information, see Appendix B: Physical Examination)

PHYSICAL EXAMINATION

- · Height and weight (refer to attached BMI chart)
- Gait (limp)
- Muscle wasting

- Inflammation (heat, redness, swelling)
- Range of motion
- · Pain on movement or at end of range

SPECIFIC ABNORMAL JOINT FINDINGS

Hip Examination

- Flexion causes external rotation
- Limited internal rotation (in flexion)
- Limited abduction
- · Fixed flexion deformity
- · Leg length discrepancy
- Trendelenburg position

Knee examination

- Quadriceps wasting
- Valgus or varus deformity
- Flexion deformity
- Patellar pain

Hand examination

- · Bouchard's and Heberden's nodes
- CMC squaring of the thumb
- **C.** Assessment to Exclude Other Diagnoses (For more details on differential diagnosis of non-osteoarthritis symptoms in the history and physical examination, refer to Appendix C: Alternate Diagnosis and Overall Assessment)

EMERGENCY CONDITIONS – URGENT REFERRAL TO SPECIALIST OR ER

- Infection
- Fracture

URGENT CONDITIONS - URGENT REFERRAL

- Malignancy
- Rheumatoid arthritis

DIFFERENTIAL DIAGNOSIS THAT MAY MIMIC OA

- Inflammatory arthropathies
- Crystal arthropathies (gout or pseudogout)
- Bursitis (e.g. Trochanteric, Pes Anserine)
- Soft tissue pain syndromes
- Referred pain
- Medical conditions presenting with arthropathy (e.g. neurologic, metabolic, etc.)

D. Investigations (For more details see Appendix D: Investigations)

- Blood tests do not diagnose OA. Blood tests may help rule out other conditions and monitor medications. Order tests when history and physical findings indicate a possible alternative diagnosis.
- X-rays are indicated for diagnostic clarification or in anticipation of orthopaedic referral. Indicate
 that the x-rays are for OA. For knees, x-rays must include standing AP, lateral, and skyline. For hip,
 specify OA hip series including lateral view of the affected hip and upper 1/3 of femur.

E. Clinical Impression and Factors to Consider Prior to Treatment and Management (Refer to Appendix C: Alternate Diagnosis and Overall Assessment.)

- Rule out alternate diagnosis
 - If the diagnosis is unclear, a Rheumatology assessment can assist with
 - Ruling out non-OA conditions or arthritic mimics
 - Diagnostic arthrocentesis
- Severity of condition (pain and function)
- Impact on independence in society
- Patient goals, expectations, preferences, past treatments
- Self-management needs/modifiable factors (e.g. assistance with weight management strategies, education about pain management, exercise, etc.)
- Psychosocial issues such as: pain amplification, depression, cognition, adherence to treatment, social support

RECOMMENDATION 2 Consider the four pillars of treatment: patient education, rehabilitation, medications and referrals (surgical and non-surgical)

Treatment of OA as a chronic disease is most effective using a multidisciplinary approach and multimodal treatments. An OA Follow-Up Patient Assessment Form is available in Appendix E.

Step 1: Patient Education

- Explain the nature of OA as a chronic disease process. Refer patient to education and treatment resources including:
 - The Arthritis Society (toll free Arthritis Answers Line 1800 321-1433 or (Web site: www.arthritis.ca)
 - Arthritis Resource Guide for BC (Web site www.argbc.ca)
 - OASIS, Vancouver Coastal Health OsteoArthritis Service Integration System (Web site: www.vch.ca/oasis)
 - Arthritis Consumer Experts (Web site www.arthritisconsumerexperts.org)
 - CAPA, Canadian Arthritis Patient Alliance (Web site www.arthritis.ca/capa)
- Emphasize the importance of appropriate exercise, joint protection, strengthening of muscles supporting the joint with activity modification.
- Emphasize the importance of developing skills to self-manage the condition (refer to attached A Guide for People Living with Osteoarthritis and patient resources). Also, consider a prescription for exercise which specifies the number of minutes per week for each of the following exercises: walking, range of motion, strengthening and, if available, aguatic exercises. Ask the person to keep an exercise diary.
- Address specific issues e.g. social and financial support, nutrition and weight management programs, pain and stress management. Refer to Overweight, Obesity and Physical Inactivity guideline at www.BCGuidelines.ca
- Awareness of private and community programs e.g. The Arthritis Society (toll free Arthritis Answers Line 1-800-321-1433 or web site www.arthritis.ca) or The Arthritis Resource Guide for BC (Web site www.argbc.ca)

Step 2: Rehabilitation

- Therapeutic exercise (range of motion, strengthening and aerobic activity).
- Generally, a sign that the patient has done too much exercise is increased pain in the joint lasting longer than 2 hours after exercise.
- Refer to physiotherapy for assessment and specific exercise recommendations if needed
- Recommend supportive footwear with shock absorption such as high-quality, well-fitted shoes and add orthotics if needed.

- One of the most cost-effective treatments for OA of the hip and knee is a cane of appropriate height used in the hand of the opposite side.
- Assistive devices include splints, gait or mobility aids, braces, home and work adaptations.
 Consider referral to Occupational Therapist, Podiatrists, Orthotists, etc. as needed and available.
- Posture and positioning recommendations for daytime or sleep.

Step 3: Medications (See Osteoarthritis (OA) Medications Table enclosure for more details)

- Provide education on role of medications (options, risk factors, side effects, complications, cost)
- Begin with monotherapy prn and add/substitute medications depending on response and side effects

MILD OR MODERATE SYMPTOMS

- Acetaminophen up to 4 grams per day is the first line medication. Consider lowering dose where there is liver disease, alcohol abuse, and for the elderly.
- NSAIDs/Cox-2 inhibitors. Match adverse effects with patient history. Avoid long term daily NSAID use.
- Joint aspiration and/or hyaluronic acid injections.

- Topicals (capsaicin or NSAIDs).
- Glucosamine, MSM and chondroitin sulfate are not recommended due to questionable evidence of treatment benefit.⁶
- Consider risks and benefits of gastroprotection. Refer to note on GI issues with oral NSAIDs below.^{4,5}

SEVERE SYMPTOMS

- Evidence of progressive bone loss
- Advanced loss of joint space in association with moderate to severe pain
- Evidence of increasing acetabular protrusion or femoral head collapse in the hip

Note: Gastrointestinal Issues with oral NSAIDS

- There is no evidence that NSAIDs alter the natural course of arthritis. The patient should be made aware that NSAIDs represent symptomatic therapy, and that the therapy is associated with some risks.⁶
- Review risk factors in Appendix B: History (long term use, older age, poor health, past history of ulcers or bleeding disorders, and more than 3 alcoholic drinks per day. Consider current medications (anticoagulants, other NSAIDs and oral steroids).^{4,5}
- Choose an NSAID appropriate to the patient based on cardiovascular risk factors. Note that COX-2 inhibitors also carry a GI risk.
- When an NSAID is essential for control of symptoms, prescribe the safest NSAID in the lowest effective dose for the shortest period of time.⁷
- Gastroprotection does not eliminate risk of ulcers, particularly for patients with high GI risk.⁵ Gastroprotection will likely reduce symptoms of dyspepsia.
- When there are risk factors, prescribe NSAIDs only for short term use along with gastroprotection: misoprostol, double dose H2 blockers and PPI have been shown to reduce the incidence of GI events.⁵
- Inform patient that GI bleeds can occur with or without warning symptoms. Patients should be informed to stop taking the medications and be reassessed if they have the following symptoms: stomach pain, heartburn, blood in vomit or stools.
- If the patient is experiencing GI problems, refer to guideline: *Dyspepsia Clinical Approach to Adult Patients* available at www.BCGuidelines.ca
- Avoid long-term daily NSAID therapy.⁷

Note: Cardiovascular risk and NSAIDS

"Health Canada acknowledges the panel's view that, as a group, selective COX-2 inhibitors are associated with an increased risk of cardiovascular events, a risk that is similar to those associated with most NSAIDs ["The cardiovascular safety concerns associated with the traditional NSAIDs are not extended to aspirin"⁸]. The panel noted that this risk is present for all patients taking anti-inflammatory agents and that it increases with longer-term use and when other risk factors, such as cardiovascular disease, are present."⁹

Step 4: Referrals (Surgical and Non-Surgical)

Note urgency on referral: mild, moderate or severe

Indications for Non-Surgical Referral:

- Refer to Rheumatology or appropriate Internal Medicine specialist for: red flag conditions (alternative diagnosis), unexpected/unusual disease progression or complications.
- Refer to PT or OT for: education on self-management or on the disease process; specific
 exercises for range of motion, strengthening, or joint protection; gait training; knee bracing; pain
 management education and techniques; mobility aids; and education for dealing with functional
 difficulties (home, work or leisure).
- Refer to Dietitian for education on weight management.
- If the patient has significant disease progression but is not a surgical candidate, for example because of significant co-morbidities, consider referral to OT for assistance with activities of daily living (ADLs).

Indications for Surgical Referral

The indications for arthroscopic knee surgery in patients with OA are similar to patients without arthritis. Arthroscopic debridement has not been shown to have any significant benefit for OA of undiscriminated cause. ¹⁰⁻¹¹

FAILURE OF A NON-OPERATIVE PROGRAM Significant pain on motion, resting pain, presence of Inadequate pain control night pain Increasing need for narcotic medications **INCREASING FUNCTIONAL RESTRICTIONS** Inability to walk without significant pain Increasing threat to patient's ability to work or live · Significantly modified ADLs: i.e. putting on shoes, climbing independently stairs, squatting and bending SIGNIFICANT ABNORMAL FINDINGS ON EXAMINATION Of the knee Of the hip Progressing deformity, especially when valgus >15° or varus >5° Decreasing range of motion. Internal rotation of less than 5° Loss of extension by 10°-15° measured in flexion Loss of flexion to less than 110° · Notable leg length discrepancy PROGRESSION OF DISEASE ON X-RAY (WEIGHT-BEARING FOR KNEE) Evidence of progressive bone loss Evidence of increasing acetabular protrusion or femoral head · Advanced loss of joint space in association with moderate to collapse in the hip severe pain

A Rheumatologist involved in the care of difficult cases may provide assistance with the timing of referral for surgical assessment.

RECOMMENDATION 3

Follow-up (Consider using a form to monitor disease progress such as provided in Appendix E: Follow-Up Patient Assessment Form.)

- Review changes in pain, function and comorbidities.
 Refer to Recommendation 1, Section A and/or Appendix A: Patient History.
- Review physical findings for red flag issues.
 Further information is found in Recommendation 1, Section C and/or Appendix C: Physical Examination.
- 3. Review effectiveness of patient education and self-directed treatment plans
 - Step 1: Self-Directed Programs (questions on disease process, particularly importance of self-management, weight loss, and joint protection)
 - Step 2: Rehabilitation Needs (home and/or community exercise programs, physical therapy for ROM and strengthening, medical devices, orthotics, cane, walker, raised seats, devices, and/or scooter)
 - Step 3: Medications: for more details refer to Appendix D: Investigations and Osteoarthritis (OA)
 Medications Table enclosure

Medications for Mild OA

- Occasional prn use of acetaminophen up to 1 gram 4 times per day and add prn NSAIDs if necessary
- If the person is on self-directed care and is doing well, then do routine follow-up unless there is a significant change in pain or function

Medications for Moderate OA

- For symptomatic OA, prescribe full dose acetaminophen (1 g 4 x day).
- Within 30 days, do a baseline haemoglobin, blood pressure, AST or ALT, and creatinine if further therapy is contemplated.
- If regular dosing of acetaminophen at 4 g/day or with NSAIDs, follow-up every 3-12 months depending on comorbidities and severity
- Consider lowering dose where there is liver disease, alcohol abuse, and for the elderly
- If the patient is using diclofenac, consider rare development of hepatitis
- Consider risks and benefits of gastroprotection. Refer to GI Issues with oral NSAIDs note in Recommendation 2: Step 3 – Medications

Medications for Severe OA

- Same as for moderate OA but review more frequently (every 1-6 months) with a view to surgical referral
- If there is an increase in severity, i.e. treatment is no longer efficacious or new symptoms, then revisit more often

Step 4: Investigations

 For monitoring liver and renal function and other possible side effects of medications (haemoglobin, blood pressure, AST or ALT, and creatinine tests). For more details refer to Appendix D: Investigations, and Osteoarthritis (OA) Medications Table enclosure Step 5: Assess Need for Non-Surgical and Surgical Referrals. Details are given in Recommendation 2: Referrals.

Coordination of Care

Treatment is multi-disciplinary involving regular follow-up. The four pillars of treatment are: patient education and self-management, rehabilitation and physical activity, medications, and referrals, as well as consideration of other supports. As with all chronic diseases, optimal outcome is achieved through a multi-disciplinary approach coordinated by the family doctor.

Rationale

Osteoarthritis (OA) was identified by the BC Ministry of Health Services, BC General Practice Services Committee (GPSC), BC Health Authorities and other stakeholders as one of the top ten chronic diseases for which the greatest opportunities exist to improve the quality of the services delivered and the outcomes for patients. OA is the most common type of arthritis and affects about 10% of the population.

Helping patients to maintain a healthy and active lifestyle is an important goal. Timely physical therapy, appropriate exercise training and patient education can affect one's ability to work and remain active. Maintaining function may reduce the long-term damage to ligaments and joints. Lack of physical activity can potentially lead to a multitude of chronic illnesses including obesity, hypertension, and depression. Treatment for the symptoms (including self management and exercise) should be encouraged. As well, risks and benefits of non-steroidal anti-inflammatory drugs (NSAIDS) should be discussed with the patient. When other treatments are no longer effective, total hip and knee replacements can be a cost-effective means of improving quality of life.

List of Acronyms

ADLs	activities of daily living	MSM	methyl sulfonyl methane
ANA	antinuclear antibody	MSP	British Columbia Medical Services Plan
AP	anteroposterior	MTP	metatarsophalangeal
AST	aspartate aminotransferase	NSAIDs	non-steroidal anti-inflammatory drugs
ALT	alanine aminotransferase	OA	osteoarthritis
BMI	body mass index	OT	Occupational Therapist
C&S	culture and sensitivity	OTC	over-the-counter
CMC	carpo-metacarpal	PIP	proximal interphalangeal
Cox-2	cyclooxygenase-2	PPI	proton pump inhibitor
DIP	distal interphalangeal	prn	as needed
GI	gastrointestinal	PT	Physiotherapist
H2RA	histamine 2-receptor antagonists	RA	rheumatoid arthritis
IADLs	instrumental activities of daily living	ROM	range of motion

References

- Canadian Institute for Health Information. Health Indicators 2007. Ottawa:2007:42.
- 2. Province of British Columbia. Ministry of Health. Information support data. 2007 Feb.
- Jordan J, Kraus V, Hochberg M. Genetics of osteoarthritis. Curr Rheumatol Rep. 2004;6(1):7-13.
- Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatology. 1999;26(s56):18-24
- Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews. 2002 Issue (4).
- Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews, 2008.
- 7. The University of British Columbia Therapeutics Initiative. Should we be using NSAIDS for the treatment of Osteoarthritis and "Rheumatism". Therapeutics Letter 1995;4:1-4. Available at URL: http://www.ti.ubc.ca/PDF/4.PDF Accessed October 30, 2007.

- Health Canada Health Products and Food Branch Marketed Health Products Directorate and Therapeutic Products Directorate. Report on the cardiovascular risks associated with COX-2-selective non-steroidal anti-inflammatory drugs. 2006. Available at: URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/sci-consult/ cox2/cox2_cardio_report_rapport_e.html Accessed October 25, 2007.
- Health Canada Health Products and Food Branch Marketed Health Products Directorate and Therapeutic Products Directorate. Panel on the safety of COX-2 NSAIDs. 2005 June 9-10; Ottawa. Available at URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/ sci-consult/cox2/index_e.html Accessed October 29, 2007.
- Kirkley A, Birmingham T, Litchfield R, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N EnglJMed 2008 Sep 11;359(11):1097-1107.
- Laupattarakasem W, Laopaiboon M, Laupattarakasem P, et al. Arthroscopic debridement for knee osteoarthritis. Cochrane Database of Systematic Review 2008, Issue 1.

Additional Supporting Materials

- American Academy of Orthopaedic Surgeons. Clinical Practice Guidelines. Available at URL: http://www.aaos.org/
- American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. JAGS 2001;49:808-823. Available at URL: http://www.americangeriatrics.org/
- American Pain Society. Pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis [summary]. American Pain Society (APS). 2002. Available at URL: http://www.guideline.gov/
- Institute for Clinical Systems Improvement. Diagnosis and Treatment of Adult Degenerative Joint Disease of the Knee. Nov. 2004. Available at URL: http://www.icsi.org/
- Harris GR, Susman JL. Managing musculoskeletal complaints with rehabilitation therapy: summary of the Philadelphia Panel evidencebased clinical practice guidelines on musculoskeletal rehabilitation interventions. J Fam Pract. 2002;51:1042-6. Available at URL: http:// www.jfponline.com/Pages.asp?AID=1364. Accessed October 25, 2007.
- Jordan KM, Arden NK et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155. Available at URL: http://ard.bmj.com/cgi/reprint/62/12/1145. Accessed October 25, 2007.
- Marshall KW & Waddell DD. Nonoperative management of osteoarthritis of the knee from a special report: osteoarthritis of the knee. 2000. Available at: http://www.physsportsmed.com

- Ontario Program for Optimal Therapeutics. 2000. Ontario Treatment Guidelines for Osteoarthritis, Rheumatoid Arthritis, and Acute Musculoskeletal Injury. Phys Ther 2004 Oct;84(10):934-72.
- Roddy E, Zhang MD et al. Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee—the MOVE consensus. Rheumatology 2005;44:67-73.
- The Second Canadian Consensus Conference. An evidence-based approach to prescribing NSAIDS in osteoarthritis and rheumatoid arthritis. Can J Clin Pharmacol. 2000;7A:4A-16A.
- United Kingdom National Health Service (NHS) Clinical Knowledge Summaries – Osteoarthritis. Available at URL: http://www.cks.nhs.uk/
- Vogels EM, Hendriks HJ, et al. KNGF-guidelines for physical therapy in patients with osteoarthritis of the hip or knee. 2003. Available at URL: https://www.fysionet.nl/dossier_files/uploadFiles/EngOsteoarthrHKGIn.pdf. Accessed October 29, 2007.
- Washington State Department of Labor & Industries. 2003. Review criteria for knee surgery. Provider Bull 2003 Dec;PB 03-16:1-7. Available at URL: http://www.lni.wa.gov/ClaimsIns/Files/OMD/MedTreat/KneeSurgery.pdf. Accessed October 25, 2007.
- Yang Y-X, Lewis J, Epstein S, Metz D. Long-term Proton Pump Inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947-2954.

Revised Date: December 1, 2009

This guideline is based on scientific evidence current as of the Effective Date.

This guideline was developed by the Guidelines and Protocols Advisory Committee, approved by the British Columbia Medical Association and adopted by the Medical Services Commission.

Enclosure

Osteoarthritis (OA) Medications Table

Appendices

Optional Decision Support Tools for the diagnosis and management of OA:

Appendix A: History

Appendix B: Physical Examination

Appendix C: Alternate Diagnosis and Overall Assessment

Appendix D: Investigations

Appendix E: Follow-Up Patient Assessment Form

Associated Documents

The following documents accompany this guideline:

- Patient Guide for People Living with Osteoarthritis
- A Guide for People with Hip Osteoarthritis
- A Guide for People with Knee Osteoarthritis
- A Guide for People with Hand Osteoarthritis
- Choosing a Complementary Therapy
- Calculation of Body Mass Index

A PDA version of this guideline is also available at www.Clinipearls.ca/BCGuidelines

Contact Information

Guidelines and Protocols Advisory Committee PO Box 9642 STN PROV GOVT Victoria BC V8W 9P1

Phone: 250 952-1347 E-mail: hlth.guidelines@gov.bc.ca Fax: 250 952-1417 Web site: www.BCGuidelines.ca

The principles of the Guidelines and Protocols Advisory Committee are to:

- encourage appropriate responses to common medical situations
- recommend actions that are sufficient and efficient, neither excessive nor deficient
- permit exceptions when justified by clinical circumstances.

Disclaimer

The Clinical Practice Guidelines (the "Guidelines") have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems.



| Guidelines & | Protocols | Advisory | Committee

Osteoarthritis (OA) Medications Table

BRITISH
COLUMBIA
The Best Place on Earth
Health Services

Effective Date: September 15, 2008
This Medication Table pertains to the Guideline Osteoarthritis in Peripheral Joints – Diagnosis and Management www.BCGuidelines.ca

Regularly review current listings of Health Canada advisories, warnings and recalls at: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/index_e.html

Drug DOSE APPROX. COST/MONT MAR 06	PHARMACARE COVERAGE	SERIOUS SIDE EFFECTS
------------------------------------	---------------------	----------------------

NON-NARCOTIC ANALGESICS Acetaminophen is as effective as oral NSAIDs for pain relief according to evidence¹.

acetaminophen generics available	650-1000 mg q4-6h OR SR caps 1300 mg q8h; max 4000 mg/day		full coverage for OA only via special authority	rare elevations of INR when using warfarin anticoagulants, liver toxicity	
mefenamic acid generics available	250 mg PO q 6h prn (generally 7 day max)	\$0.34/tab	full coverage for lowest cost brand	Similar to NSAID risks below	

NSAIDs Acetaminophen is the first choice. Trials have not demonstrated any consistent superiority of one NSAID over another²

acetylsalicylic acid (enteric-coated) generics available	2600-5400 mg PO daily, divided q4-6h	\$3-\$6	full coverage	The side-effects listed below apply to NSAID class of drugs:
ibuprofen generics available	200-500 mg bid-tid up to 1500 mg 24hr	\$3-\$10	full coverage	GI ulceration, perforation with or without bleeding
naproxen generics available	250-500 mg bid-tid max 1500 mg/day	\$10-\$14	full coverage	severe diarrheahepatotoxicity
diclofenac generics available	50 mg P0 bid-tid or 75mg bid; max 150 mg/day	\$24-\$40	partial coverage or full coverage with special authority	renal impairmentcardiovascular eventsCHF; angina;
diflunisal generics available	250-500 mg PO q12h	\$27-\$32	partial coverage or full coverage with special authority	hypertension; arrhythmia; bronchospasm;
flurbiprofen generics available	50-100 mg P0 bid-tid; max 300 mg/day	\$16-\$32	partial coverage or full coverage with special authority	pulmonary edema • blood dyscrasias
indomethacin generics available	25-50 mg bid-tid; max 200 mg/day	\$5-\$15	partial coverage or full coverage with special authority	thrombocytopenia erythema multiforme symptoms of aseptic
ketoprofen generics available	75 mg P0 tid or 50 mg P0 qid; max 300 mg/day	\$21	partial coverage or full coverage with special authority	meningitis • blurred or diminished
meloxicam generics available	7.5-15 mg PO od	\$17-\$20	no coverage (full coverage with special authority)	vision • fluid retention
nabumetone generics available	500 mg	\$30-\$60	no coverage (full coverage with special authority)	
piroxicam generics available	20 mg PO qd	\$22	no coverage (full coverage with special authority)	
sulindac generics available	150-200 mg P0 bid; max 400 mg/day	\$24-\$30	no coverage (full coverage with special authority)	
tiaprofenic acid generics only for 300 mg	Either 300 mg bid or SR 600 mg	\$25-\$40	no coverage (full coverage with special authority)	
tolmetin generic available	200-600 mg P0 tid; max 1800 mg/day	\$40-\$80	no coverage (full coverage with special authority)	
etodolac generics available	300 mg PO bid	\$51	no coverage	Gl bleed, erythema multiforme, bronchospasm, hepatotoxicity
ketorolac generics available	10 mg PO q4-6h; max 40 mg/day; short-term use only	\$59	no coverage	peptic ulcer, with/without bleeding; fatalities in the elderly

Drug	Drug DOSE		PHARMACARE COVERAGE	SERIOUS SIDE EFFECTS		
COX 2 inhibitors						
celecoxib (no generics)			no coverage; full coverage with special authority	as above in NSAIDs		
NSAIDs (Topicals)						
diclofenac sodium	40 drops, applied qid	\$50	no coverage	colitis, arrhythmia, 1% may develop hepatitis		
Other Topicals						
menthol	apply tid-qid	\$7.40/50g tube	no coverage	allergic skin reaction		
capsaicin	apply tid-qid to unopened skin	\$20-\$40	no coverage	skin irritation; sun sensitivity		
INTRA-ARTICULAR MED	S (injection): steroids					
triamcinolone	2.5-40 mg intra-articularly	\$2.60-\$5.50 /injection	full coverage	anaphylaxis, masking of infections		
NARCOTICS (oral)						
codeine* generics available	15-60 mg P0	\$13-\$18	full coverage *Requires a controlled prescription form when prescribed as a single entity or when included in preparations with > 60mg codeine	common: CNS depression; constipation; sweating; nausea and vomiting		
acetaminophen with codeine 15 mg and 30 mg (Emtec® acetamin- ophen 300 + codeine 30 mg, no caffeine)			full coverage	major: respiratory depression; circulatory depression; cardiac arrest; hypersensitivity		
ASA with codeine 15 mg or 30 mg	individualized	\$0.07- \$0.18/tab	full coverage	other: arrythmias; syncope; headache; dysphoria; agitation;		
oxycodone with acet- aminophen 5mg/325mg 2.5mg/325mg	individualized	\$0.13 \$0.61/tab	full coverage	seizure; urinary retention; blood dyscrasias; potential for dependency;		
hydromorphone*	P0: 2-4 mg q4-6h	\$30-\$90	full coverage for immediate release–controlled release (long-acting) is special authority	serious outcomes when combined with CNS depressants (e.g.,		
morphine*	PO initial dose: 10 mg q4h 0R 30 mg SR q12h; titrate dose appropriately	\$33-\$52	full coverage	alcohol), acetaminophen: liver		
oxycodone*			full coverage for immediate release—controlled release (long-acting) is special authority	toxicity .		
tramadol with acetaminophen (Tramacet®) 37.5mg/ 325mg OR single entity controlled release (Zytram XL®) 150 mg, 200 mg, 300 mg, 400 mg	Tramacet®: 1-2 tabs q4-6h PRN; max 8 tabs/day; max 5 days of treatment Zytram XL®, P0 initial dose: 150 mg q24h; titrate dose appropriately	Tramacet®: \$77-\$153 Zytram XL®: \$48-\$120	no coverage	seizures (esp. with antidepressants); convulsions; allergic reactions; respiratory depression; addiction; cancer; pregnancy issues; dizziness; nausea		

Drug	DOSE	APPROX. COST/MONTH MAR 06	PHARMACARE COVERAGE	SERIOUS SIDE EFFECTS
Viscosupplementation	(Devices as per Health Canada)			
hyaluronic acid Durolane®, Hyalgan®, Orthovisc®, Ostenil®, Neovisc®, Synvisc®	1-3 injections	\$200-\$400 per vial	no coverage	allergic reaction

Herbals and supplements: not recommended

Products with a DIN (Drug Identification Number) have been supported by good-quality studies for safety and effectiveness. Products with a NPN (Natural Health Product Number), USP number (US Pharmacopeia), Consumers Lab logo, or NSFTM international certification may ensure quality but do not ensure effectiveness.

chondroitin sulphate	200-400 mg bid-tid	\$10	no coverage	unknown and may have serious interactions with
glucosamine sulphate	500 mg tid	\$50	no coverage	other drugs
methylsulfonylmethane (MSM)	1-3 grams bid	\$10-\$48	no coverage	
s-adenosylmethionine (SAMe)	400 mg tid-qid 200 mg tid	\$120	no coverage	

^{*}Requires the use of a Controlled Prescription Program Form (formerly triplicate prescription program) Special Authority criteria and forms are available on the PharmaCare Web site at http://www.health.gov.bc.ca/pharme/sa/criteria/formsindex.html

Note: Cardiovascular risk and NSAIDS

"Health Canada acknowledges the panel's view that, as a group, selective COX-2 inhibitors are associated with an increased risk of cardiovascular events, a risk that is similar to those associated with most NSAIDs [The cardiovascular safety concerns associated with the traditional NSAIDs are not extended to aspirin³]. The panel noted that this risk is present for all patients taking anti-inflammatory agents and that it increases with longer-term use and when other risk factors, such as cardiovascular disease, are present."⁴

References

- 1. Tanna, S. Osteoarthritis opportunities to address pharmaceutical gaps. 2004. Available at URL: http://mednet3.who.int/prioritymeds/report/background/osteoarthritis.doc. Accessed October 30, 2007.
- 2. The University of British Columbia Therapeutics Initiative. Should we be using NSAIDS for the treatment of Osteoarthritis and "Rheumatism". Therapeutics Letter 1995;4:1-4. Available at URL: http://www.ti.ubc.ca/PDF/4.PDF. Accessed October 30, 2007.
- 3. Health Canada Health Products and Food Branch Marketed Health Products Directorate and Therapeutic Products Directorate. Report on the cardiovascular risks associated with COX-2-selective non-steroidal anti-inflammatory drugs. 2006 June. Available at URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/sci-consult/cox2/cox2_cardio_report_rapport_e.html. Accessed October 25, 2007.
- 4. Health Canada Health Products and Food Branch Marketed Health Products Directorate and Therapeutic Products Directorate. Panel on the safety of COX-2 NSAIDs. 2005 June 9-10; Ottawa. Available at URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/sci-consult/cox2/ index e.html. Accessed October 29, 2007.

Resource Documents

Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association; 2008 Canadian Pharmacists Association, Therapeutic Choices. 2008. Drug Prices: obtained from PharmaNet, for prescription medications, and at various Victoria, BC retail outlets for non-prescription medications.

Notes:

- A. If a medication has a generic equivalent, the drug cost is for the generic product.
- B. For prescription medications, the price does not include professional fees.
- C. For non-prescription medications, the price does not include applicable sales taxes.
- D. Where a price range is indicated, this reflects the cost based on minimum and maximum dose ranges.

OSTEOARTHRITIS - HISTORY

This Optional Decision Support Tool pertains to the Guideline: Osteoarthritis in Peripheral Joints - Diagnosis and Treatment www.BCGuidelines.ca

ніѕто	RY – FEA	TURES TO CONSIDER					
	E LOCATIO						
Onast		Acuto		Cradual			
Onset Trauma		Acute Yes		Gradual No			
		Red flags for inflammation*		Osteoarthritis			
Type Locatio				Monoarticular		Polyarticular*	
Feature		Transient morning stiffness		Painful crepitus		Sensation of instability	
, oatare		Aware of deformity	_	Impaired use of joint (li		Loss of range of motion	
Refer to	Guideline	: Rheumatoid Arthritis – Diagr	osis and Mar	nagement at www.BCGu	idelines.ca		
INFLAM	MMATOR	Y/NON-INFLAMMATORY A	RTHRITIS – [DIFFERENTIATION" (No	te: a patient with RA r	nay develop OA)	
FEATUR	E	NON-INFLAMMATORY		INFLAMMATORY			
Joint p	ain	With activity		With activity a	at rest		
Joint s	welling	Bony		Soft tissue			
Joint d	eformity	Common		Common			
Local e	erythema	Absent		Sometimes			
Local v	warmth	Absent/Minimal		Frequent			
Mornin	ng stiffnes	s <30 minutes		>30 minutes			
Systen	nic sympt	oms Absent		Common			
Joint d	istributior	n PIP (Proximal Inter DIP (Distal Interpha CMC (Carpo-Meta knee, first MTP (Ma	alangeal), first carpal), hip,		PIP/MCP,		
urn, walk	back and	essed using the Timed Up & d sit. Normal time is between	7-10 seconds	s. Further assessment is	suggested for those wh		
		Society. The Timed Up & Go	lest for Fall	Risk Assessment 2001,4	9(5):666		
Pain Fe	eatures						
	Localized	l		Present at rest			
	Aggravate	ed by motion/weight bearing		Influenced by weather			
	Night pai			Radiating widely aroun			
	None/mile	d pain on motion	•	does not prevent any a	activity.	pending. They may experience	e some pain but it
			•	They usually do not red	<u> </u>		
	Moderate	e pain on motion	•	that limits their activities	es to some degree. For	pending. They experience pair example, patient experiences	trouble walking up
					•	nding for long periods of time	
			•	They occasionally need			
	Severe pa	ain on motion	•		e, patient experiences p	cing pain. The pain restricts the pain walking up and down sta	
			•	They need pain medica			
Walking	r canahili	ty without significant pain	<u> </u>	> 5 blocks	anon most of tile tille.		
vvainiili	y capabili	ry without significant pail		1-5 blocks			
				Less than 1 block			
				Household ambulation			
				Unable to walk without			
PAIN SUI	MMARY S	Scale between 1 and 10 →			AIN CONTROL Satisfi	ed Indicated by:	□ Patient

☐ Physician

Indicated by:

☐ Unsatisfied

REVIEW SYSTEMS

Overall risk factors for diseas	se:							
☐ Obesity	☐ Muscle weakness	☐ Heavy physical activity						
☐ Inactivity	Previous trauma	 Reduced proprioception 						
☐ Family history	☐ Mechanical factors							
Review of risk factors for treatment with NSAIDs:								
GI								
☐ History of peptic ulcer	History of GERD symptoms	☐ Glucocorticoids						
☐ Tobacco use	☐ Liver disease	☐ Anticoagulant						
☐ Alcohol abuse	☐ Age > 65							
☐ Comorbidities (Describe):								
Renal								
☐ Calculated eGFR < 60	☐ Anti-hypertensive medication	☐ Diuretic						
Cardiovascular								
☐ Hypertension	☐ Ischemic heart disease	☐ Heart failure						

Appendix B

OSTEOARTHRITIS - PHYSICAL EXAMINATION

This Optional Decision Support Tool pertains to the Guideline: Osteoarthritis in Peripheral Joints – Diagnosis and Treatment www.BCGuidelines.ca

Gait □ Normal □ Abnormal	Leg length d standing (gre Left Right	iscrepancy while eater)?	Muscle wa □ Yes □ No	sting?		Pain progression: ☐ Yes ☐ No
Deformity while standing? ☐ Yes ☐ No	Pelvis level? ☐ Yes ☐ No		Pain with a □ Yes □ No	any motion?		
			Pain range	(1 = least pain; 1	0 = m	ost pain):
Loss of ROM?	☐ Yes		□ No			
ROM knee observations (examine standing)		Describe the range that Fixed flexion deformit None		es through Moderate 5	5º-15º	☐ Severe > 15°
		Flexion range of motion Mild > 115°		ate 90º - 115º		Severe < 90°
		Genu Valgum (knock-l Left: Right:	knee) Mild Mild	☐ Moderate☐ Moderate	<u> </u>	Severe Severe
ROM hip observations		Flexion deformity (FFI	D) test with n Mild 0º-5º	naximum flex of Moderate		
		Flexion range of motio	on: Mild > 115 ⁰	☐ Moderate	90º-1	15 ⁰ □ Severe < 90 ⁰
		Progression: External rotation with Yes N		☐ No y sign of OA): ☐ Left		Right
		Limited internal rotation		□ Left		Right
		Limited abduction:	loderate	□ Severe		Left □ Right
Joint		□ Effusion mild, mode□ Crepitus□ Warmth				Localized swelling Bony enlargement
Di : 15 0 // : 5		Progression? Ye		□ No		
Physical Exam Summary (abnormal fi	ndings)	□ M	lild	■ Moderate		Severe

Appendix C

OSTEOARTHRITIS – ALTERNATE DIAGNOSIS AND OVERALL ASSESSMENT

This Optional Decision Support Tool pertains to the Guideline: Osteoarthritis in Peripheral Joints – Diagnosis and Treatment www.BCGuidelines.ca

Λ	17	ER	M	ΛТ	П	Λ	CI	W	\mathbf{a}	2	c

Consider alternate diagnosis of non-osteoarthritis symptoms for history and physical examination (amplification of condition)

Consider alternate diagnosis of non-osteo	arthritis symptom	s tor ni	story and physical examination	on (ampiii	ication of con	naition)					
Red flag indications											
☐ Acute severe pain		_	icant trauma (e.g. fracture)		.						
☐ Fever, night sweats or significant weig			or diffuse muscle weakness		Hot and swo	llen joint *(not OA)					
Neurogenic pain pattern		Claud	ication pain pattern								
Red flag condition suspected											
Infective arthritis		Bacte			Viral						
		Tuber	culosis								
Inflammatory arthritis*		React	ive		Gout						
,			matoid*								
Connective tissue disease		SLE			Scleroderma	ı					
Other medical conditions presenting with p	ain 🗅	Polvn	nyalgia rheumatica		Referred pair	n (i.e. pain originating in the back					
J		•	idosis		masquerading as hip pain or hip pain radiating to the knee)						
		Thyro	id disease								
		Fracti	ıre								
		Infect	ive endocarditis		Diabetic chei	iroarthropathy					
					Paraneoplast	tic syndromes					
					Multiple mye	eloma					
Consider other issues:											
☐ Fear/avoidance behaviour		Pain a	amplification		Over-protect	otective partner-spouse					
 Passive attitude to rehabilitation 		Impai	red sleep because of pain	 Lack of social/financial support 							
☐ Substance overuse/abuse		Depre	ession	☐ Poor adherence to exercise							
*Review guideline: <i>Rheumatoid Arthritis – Diagnosis</i>	and Management at v	www.BC	Guidelines.ca								
OVERALL ASSESSMENT											
If osteoarthritis is suspected, an overall asses Consider the following criteria:	sment of the condi	tion is i	mportant. Ask what problems th	ne patient	is having and	how much it impacts their life.					
FEATURE	NONE		MILD		MODERATE	SEVERE					
Pain											
Overall function											
Abnormal findings on physical exam											
Ability to function at work											
Ability to enjoy recreational activities											
What are the modifiable factors? From this	overall impression	, anticip	ate the nature of treatment:								
Likely estisfactory/oufficient recovers to the	on pharmacalasi-	nd/a==	sharmaaalaaja traatmant	□ V-	o □ N-						
Likely satisfactory/sufficient response to no		and/or p	mammacologic treatment	☐ Ye							
Referral for non-surgical specialist assessn	nent indicated			☐ Ye							
Referral for surgical assessment indicated			☐ Ye	s 🛭 No)						

Appendix D

OSTEOARTHRITIS - INVESTIGATIONS

This Optional Decision Support Tool pertains to the Guideline: Osteoarthritis in Peripheral Joints – Diagnosis and Treatment www.BCGuidelines.ca

There are no blood tests to diagnose osteoarthritis. Blood tests are done to rule out other conditions and monitor the disease and/or medications.

Order tests when history and physical findings indicate and consider inflammatory versus non-inflammatory presentations (non-OA or OA respectively)

INVESTIGATIONS TO CONSIDER OF OTHER CONDITIONS SUSPECTED										
Blo	ood work									
	Hematology profile	Test for chronic or inflammatory condition (baseline to monitor NSAID treatment).								
	Creatinine	Test renal function if considering NSAID use.								
	ESR	Use when considering rheumatoid condition, multiple myeloma or infection. See guideline: <i>Erythrocyte Sedimentation Rate</i> available at www.BCGuidelines.ca								
	C-Reactive Protein	Use in septic arthritis diagnosis and to monitor treatment. Selectively consider use when it is important to rule out inflammatory conditions								
	ANA	Use when considering connective tissue disease – see guideline: Antinuclear Antibody (ANA) Testing for Connective Tissue Disease at www.BCGuidelines.ca								
	Rheumatoid Factor (RF)	Review guideline: Rheumatoid Arthritis - Diagnosis and Management at www.BCGuidelines.ca								
	AST	Consider AST (aspartate aminotransferase test) for diagnosing and monitoring liver disease when considering NSAID use.								
	Crystals C&S	□ Microscopy								
DI	AGNOSTIC IMAGING									
		lained joint pain or in anticipation of orthopaedic/rheumatologic referral. Specify the x-rays are for OA.								
	hips – specify OA hip series including lateral view of the affected hip and upper 1/3 of femur.									

Appendix E

OSTEOARTHRITIS – PATIENT ASSESSMENT FOLLOW-UP

This Optional Decision Support Tool pertains to the Guideline: Osteoarthritis in Peripheral Joints – Diagnosis and Treatment www.BCGuidelines.ca

Pain														
Satisfactory pain control		yes		no										
Night pain affecting sleep		yes		no										
Overall pain rating (0= none; 10= most)		,												
Satisfaction with Function														
Walking		yes		no										
Interference with activities of daily living (ADLs or IADLs)		yes		no										
Work		yes		no										
Recreation		yes		no										
Patient Education														
Self-management completed		yes		no										
Weight loss/diet plan needed		yes		no										
Joint protection		yes		no										
Rehabilitation and Exercise		Toler					Effec				Chang			
Home exercise program		yes		no			yes		no		yes		no	
Community exercise program		yes		no			yes		no		yes		no	
Physical therapy for ROM and strengthening		yes		no			yes		no		yes		no	
Medical devices		yes		no			yes		no		yes		no	
	-1-1-													
Orthotics			ied				Suita							
Ormonics	\Box	yes		no			yes		no					
Cane/walker		yes		no			yes		no					
		yes yes	0	no no			yes yes	0	no no					
Cane/walker Raised seats/devices		•					•				Chang	e pla	n	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects)		yes Toler	ated				yes	ctive			Chang ves		n	
Cane/walker Raised seats/devices		yes Toler yes		no			yes Effect yes	ctive	no		yes	e pla		
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs		Toler yes yes	ated	no no			yes Effect yes yes	ctive	no		yes yes		no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection		Toler yes yes yes	ated	no no no no		0	yes yes yes yes	ctive	no no no no	<u> </u>	yes yes yes		no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor	0	Toler yes yes yes yes	ated	no no no no			yes yes yes yes yes	etive	no no no no		yes yes yes yes		no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates		Toler yes yes yes yes yes	ated	no no no no no			yes yes yes yes yes yes yes yes	etive	no no no no no		yes yes yes yes yes		no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor		Toler yes yes yes yes yes yes	ated	no no no no no no			yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no		yes yes yes yes yes yes		no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates		Toler yes yes yes yes yes	ated	no no no no no			yes yes yes yes yes yes yes yes	etive	no no no no no		yes yes yes yes yes		no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates		Toler yes yes yes yes yes yes	ated	no no no no no no			yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no		yes yes yes yes yes yes		no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles		Toler yes yes yes yes yes yes	ated	no no no no no no			yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no		yes yes yes yes yes yes		no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no	٥	0	yes Effect yes yes yes yes yes yes yes	etive	no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no	٥	0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no	٥	0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no	٠	0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no no	
Cane/walker Raised seats/devices Medications for OA (names, doses and side effects) Acetaminophen NSAIDs Gastro protection Cox-2 inhibitor Opiates Injectibles Referrals Surgical		Toler yes yes yes yes yes yes yes	ated	no no no no no no no		0	yes Effect yes yes yes yes yes yes yes	etive	no no no no no no no no		yes yes yes yes yes yes		no no no no no no	

Osteoarthritis

A Guide for People Living with Osteoarthritis

Effective Date: September 15, 2008

What is Osteoarthritis?

Osteoarthritis (OA) is the most common type of arthritis. It can happen in any joint but is most often in the hands, hips, knees and spine. In osteoarthritis, there is a breakdown of the cartilage on the ends of bones. Healthy cartilage is firm, rubbery and smooth. It acts as a shock absorber. The slippery surface of cartilage allows joints to glide easily. Usually in early OA there is no swelling. Later, bits of cartilage may break off and disturb other tissue in the joint. This can cause pain and swelling. Over time, the bones can change, creating bumps, called spurs. The cartilage may wear away completely and bones may rub together.

What causes Osteoarthritis?

Researchers are studying how the cartilage breaks down. They have found some enzymes that damage cartilage. These enzymes can occur with extra stress in the joint. Factors that increase your chance of getting OA include:

- Previous injury to the joint
- Repeated stress on the joint, such as heavy physical activity or being overweight
- Heredity, and
- Getting older.

What can I do about Osteoarthritis?

Learn about OA. Become skilled at setting goals and solving problems. These skills help you apply the things you learn. A self-management program, such as Arthritis Self-Management Program (ASMP) from The Arthritis Society is a good place to start. If not available or convenient, try other group or home-based programs for relaxation, weight control, and balancing exercise with rest to improve your comfort and function.

Regular exercise helps reduce pain and improve function because:

- strong muscles help protect painful joints, help maintain balance and prevent falls;
- joint movement helps nourish the cartilage;
- flexible muscles allow the body to use less painful positions; and
- fitness exercises help maintain body weight, reduce stress, improve sleep and reduce fatigue.

Consider walking, swimming, Pilates and Tai Chi.

Generally, a sign that you've done too much exercise is increased pain in the joint lasting longer than two hours after the exercise has ended. Next time do a bit less. If you have difficulty exercising, you may need advice from a physical therapist.







An occupational therapist can advise you how to reduce stress to your joints while continuing your daily activities. This may include advice about:

- Methods to make daily tasks easier including tools such as jar openers;
- Proper posture, sleeping positions, and work station set up;
- Proper footwear and orthotics supports;
- Splints or braces to protect joints, and
- Getting a better sleep including mattresses, pillows and relaxation.

There are many medications available including creams and gels, acetaminophen (such as Tylenol®), non-steroidal anti-inflammatory drugs (NSAIDs) and injections. All medications have possible side effects whether taken alone or with herbal or over-the-counter medication. Your doctor will help you find a medication to reduce your pain with minimal risks. Your pharmacist can also help with medication questions. Your doctor may recommend surgery if the joint is significantly damaged or if your pain is not well controlled. Surgery for OA can include removing torn cartilage from the joint, realigning bones around the knee or replacing the joint with an artificial joint.

How do I learn more?

- The Arthritis Helpbook by K. Lorig and J. Fries (at libraries and bookstores and The Arthritis Society)
- Arthritis Information Line (toll free): 1-800-321-1433 (or 604-875-5051) or info@bc.arthritis.ca
- The Arthritis Society website: www.arthritis.ca/bc
- The Arthritis Resource Guide for BC website: www.argbc.ca
- Arthritis Foundation: www.arthritis.org
- Find a Physical Therapist in BC at www.bcphysio.org or call 604-736-5130
- Find an Occupational Therapist in BC at http://www.bcsot.org or call 604-736-5645 or 1-888-736-5645.
- Dial-a-Dietician at 1-800-667-3438 or 604-732-9191
- BC Primary Health Care Web site: http://www.primaryhealthcarebc.ca
- BC Health Guide Handbook or online at: www.bchealthguide.org.
- BC Nurse Line (24 hour advice & information) at 1-866-215-4700 or 604 215-4700 or hearing impaired 1-866-TTY-4700
- OASIS, Vancouver Coastal Health OsteoArthritis Service Integration System (Web site www.vch.ca/oasis)
- Arthritis Consumer Experts (website www.arthritisconsumerexperts.org)
- CAPA, Canadian Arthritis Patient Alliance (website www.arthritis.ca/capa)
- Telephone book: (1) Red Cross Equipment Loans & (2) Recreation Centres

Hint: When searching the internet for information, look for sites with ".edu", ".org" or ".gov". Universities and governments are often reliable sites. Be aware that some sites with .com may be selling products.

Hip Osteoarthritis

A Guide for People with Hip Osteoarthritis

Effective Date: September 15, 2008

What happens in hip osteoarthritis?

When a hip joint gets osteoarthritis (OA) the joint becomes painful and stiff and muscles become weak. When the hip is stiff, the lumbar spine (lower back) moves more. When hip muscles are too weak to keep the pelvis level during walking, the body may sway sideways with each step. These changes can increase low back discomfort. Keeping the hip joint flexible and strong helps balance forces in the joint, and nourishes the cartilage. It also helps reduce strain in other joints.

Common features of hip OA are:

- Pain and stiffness at the front of the hip or groin;
- Rotation stiffness that causes the toe to point outwards;
- Weakness of muscles which pull the leg out and keep the pelvis level;
- Weakness of the buttock muscles which pull the leg back, and
- Belly muscles too weak to stabilize the lower back.

What can I do about hip osteoarthritis?

Learn as much as you can about OA. Read A Guide for People Living with Osteoarthritis including the list of places to get more information.

- Maintain a healthy weight. When you walk fast or on stairs, the forces in your hip are seven times your body weight. Losing ten pounds means 70 pounds less pressure during those activities.
- A cane used in the opposite hand lowers hip pressures.
- Wear shoes that cushion and support. Consider custom insoles.
- Maintain aerobic fitness by walking, bicycling or swimming.
- Try the exercises on the back of this page. Start gently and increase slowly. If they don't help, or if they increase pain, ask your doctor to recommend a physiotherapist (PT). A PT assessment will identify where you are tight, which muscles are weak, how your body compensates and what causes pain. A personal exercise program can be created for you.
- If exercise causes more joint pain for over two hours, do less next time.








To strengthen, hold about 3 seconds and repeat 10 – 15 times. (3-4 times/week)


1. Strengthen belly muscles

Lie on your back with knees bent and feet flat. Tighten lower belly muscles by pulling your belly button down to your spine. Breath normally.




2. Strengthen hip muscles at back

Lie on your back with knees bent, feet flat and belly tight. Squeeze buttocks and lift hips off bed. If this is too easy, try it one leg at a time.



3. Strengthen hip muscles at side

Lie on your side with lower leg bent and top leg in line with your body. Lift the top leg without rolling your pelvis. Don't lift leg high, just level.



Hold stretches for 20 seconds. Repeat 2 –3 times. (daily)

4. Stretch the front of your hip

Stand against a wall at an edge or doorway, so half your body leans against the wall. Tighten your belly muscles. Step back with the free leg just far enough to feel a stretch at the front of your hip. Keep your body touching the wall.



5. Stretch hip rotation

Lie on your back. Slowly roll both knees and thighs inward, toward each other keeping knees straight. Return to starting position.



For advice about planning an exercise program, see *The Arthritis Helpbook* by Lorig and Fries, available at libraries, bookstores and The Arthritis Society.

Knee Osteoarthritis

A GUIDE FOR PEOPLE WITH KNEE OSTEOARTHRITIS

Effective Date: September 15, 2008

What happens in knee osteoarthritis?

Osteoarthritis (OA) is a disease of the cartilage. When a knee joint gets OA it feels stiff, sore and weak. Knee cartilage can have a healthy response to exercise. Forces in the knee joint influence the risk of osteoarthritis. Too much force can damage the cartilage and increase the risk of getting OA. This can happen if a joint is injured, or if a person is overweight. People with chronic knee pain are more likely to develop OA if their knee muscles are weak and the joint is stiff. Exercise is important to keep the muscles strong, the joint flexible and the cartilage nourished.

Common features of knee OA are:

- · weakness when getting up from a chair;
- pain when going up or down stairs; and
- stiffness when trying to bend or straighten the knee.

What can I do about knee osteoarthritis?

Learn as much as you can about OA. Start by reading *A Guide for People Living with Osteoarthritis* including the list of places to get more information.

- Maintain a healthy weight. If you are heavy, each pound of weight you lose can result in 4 pounds less force in your knee at each step.
- Keep your thigh muscles strong and your knee flexible so it bends and straightens all the way. Good balance is important too.
- Wear good shoes that absorb shock and have firm support around heels. Consider orthotics in shoes and a knee brace if pain continues.
- Avoid sitting on low chairs. You can protect a knee by using a raised toilet seat and a cane. Consider avoiding stairs.
- Maintain aerobic fitness by walking, bicycling or swimming.

Try the exercises on the back of this page. Start gently. Increase slowly.

- If exercise causes more joint pain for over 2 hours, do less next time.
- If these exercises do not help or if they increase your pain, ask your doctor to recommend a physiotherapist (PT). A PT assessment will identify where you are tight, which muscles are weak, how your body compensates and what causes pain. A personal exercise program can then be created for you.







To strengthen, hold about 3 seconds and repeat 10 – 15 times. (3-4 times/week)

1. Strengthen knee flexors - standing

Stand on one leg while holding onto a firm object for support. Keep your body upright and abdomen tucked in. Bend the opposite knee, pulling your foot toward your buttock as far as possible. If this is easy you can put a small weight on your ankle or wear a heavy shoe.



2. Strengthen thigh muscles


Stand with your back against a wall. Feet are shoulder width apart and about 6 inches from the wall. Keep your abdominals tight and slide down the wall until your knees are abut 30 – 45 degrees. Only go as far as you can feeling safe and without pain. A rolled towel between your knees helps alignment. Some people may need additional support – such as a nearby countertop to assist in returning to standing.



Hold stretches for 20 seconds. Repeat 2 –3 times. (daily)


3. Stretch knee & gently tighten thigh

Lie on your back with your legs straight. Pull your toes up towards you and push the back of your knee down into the bed or floor. When the back of your knee is pushed into the bed or floor your heel should be able to rise a bit.



4. Stretch Hamstring muscles

Sit on the edge of a chair, with one leg out straight and your foot on a low stool or thick book. Pull toes up and keep the low back straight. Slowly bend forward from your hips without twisting your pelvis. You should feel the stretch at the back of your leg and knee.



For advice about planning an exercise program, see *The Arthritis Helpbook* by Lorig and Fries, available at libraries, bookstores and The Arthritis Society.

Content prepared by Mary Pack, Arthritis Program, Vancouver Coastal Health. Illustrations prepared for BCMA® by Meike Boer Design

Hand Osteoarthritis

A Guide for People with Hand Osteoarthritis

Effective Date: September 15, 2008

What happens when osteoarthritis is in the hand?

Osteoarthritis (OA) is a disease of the cartilage. Without healthy cartilage, pressure is put on bones. Ligaments across joints may stretch. The finger joints may have periodic, painful swollen cysts. Eventually bone spurs or nodes grow around the joint and it may become crooked and stiff. OA in the hand usually affects the two sets of joints that are closest to the fingertips. The base of the thumb, near the wrist, is a common place for OA. Wrist OA may occur after injuries to the wrist.

Common features of hand OA are:

- finger joints get bigger, these are nodes or bone spurs;
- pain or aching at rest or when holding things;
- stiffness in the fingertips causing difficulty making a fist; and
- stiffness of the thumb so it is difficult to hold a large glass or bottle.

What can I do about Hand Osteoarthritis?

Learn as much as you can about OA. Read A Guide for People Living with Osteoarthritis including the list of places to get more information.

- Exercise your hands to stretch tight joints and to keep the cartilage healthy. Exercising in warm water may help stiffness and pain.
- Protect joints by using jar openers, key holders and large handled tools. Avoid extreme or prolonged positions and repetitive activities.
- Consider splints for your thumb or wrist.
- Try the exercises on the back of this page. Start gently. Increase slowly. If
 they don't help, or if they increase pain, ask your doctor about a Certified Hand
 Therapist, Occupational Therapist (OT) or Physiotherapist (PT). These specialists
 will assess you, teach you a personal exercise program and give advice about joint
 protection.
- If exercise causes more joint pain for over 2 hours, do less next time.







Hold stretches for 20 seconds. Repeat 2 - 3 times. (daily)

1. Stretch your fingers

Gently curl the tips of your fingers down to touch the base of each finger, then the middle of the palm then open to the straight position. Do this in a sink of warm water.





2. Stretch your thumb

Touch the tip of your thumb to the tip of each finger, making a circle (not a "D"). Open your hand completely after each touch.



3. Stretch your wrist

Put your palms together with your fingertips near your chin. Slowly lower your hands towards your waist, by moving your elbows apart. Keep your palms together to stretch the wrist. Watch yourself in a mirror to see if both hands are equal.



Protect your joints

A good, stable thumb position

An unstable thumb position to avoid



A good thumb splint

It's good to use large handles





Osteoarthritis

CHOOSING A COMPLEMENTARY THERAPY

Effective Date: September 15, 2008

Complementary therapies are activities or supplements that are added to or used as an alternative to medical care. Generally, they have not been validated by quality scientific research so the risks and any benefits are not clear. The use of complementary therapy is not endorsed. This guide is provided for your information. It is a guide about questions to ask and precautions to take if you are considering the use of a complementary therapy.

Complementary therapies include a wide range of treatments such as:

- dietary changes;
- vitamins, minerals, herbal supplements, etc.;
- techniques such as relaxation, visualization, meditation; and
- magnets, massage, therapeutic touch, etc.

What should I consider before starting?

Before starting, make sure that you are already eating healthy food, exercising regularly and following the advice of your health care providers. Nutrients from food sources are absorbed best so improve your diet before adding dietary supplements.

1. Have a specific goal when trying a new therapy.

Know the specific action and benefit you are trying to achieve and the timeline.

2. Do your research first.

- a. Use reliable Internet resources, such as university, government or non-profit agency websites (e.g. The Arthritis Society).
- b. Use reliable books or written publications/journals.
- c. Ask questions.
 - Is the evidence offered convincing to the general scientific/medical community? If not, why not?
 - How much, how often and how long is necessary to get benefit?
 - · How much will the consultations, procedures, and supplements cost?
 - Does it interact with other medications/supplements or therapies?
 - · What are the possible risks and side effects?
 - · Will it interfere with other medical conditions?
 - Is this therapy accepted by the broad medical community?







3. Inform your health care providers.

- a. Begin by discussing options with your doctor, nurse, pharmacist, physiotherapist, etc.
- b. Tell your health care providers about all complementary therapies you are using.
- c. Provide a list of all current medications, supplements and therapies that you are taking or are not taking that were prescribed.
- d. Inform your health care provider of any prescribed therapies you are not using.

4. Use only health products that have proper certification.

Products with a DIN (Drug Identification Number) have been supported by good-quality studies for safety and effectiveness. Products with a NPN (Natural Health Product Number), USP number (US Pharmacopeia), or Consumers Lab logo, or NSF™ international certification may ensure quality but do not ensure effectiveness.

5. Take the same precaution you would with conventional medicine.

Supplements should be treated as drugs. They may have side effects.

6. Try only one new therapy at a time and assess benefit.

Continue the therapy only if it works, with no side effects, and is affordable.

7. Before surgery, stop dietary/herbal supplements for several weeks.

Many supplements have biological effects (such as increased bleeding) that interact with medicines used during or after the operation. Provide a list of all current medications, supplements and therapies to your health care providers.

Resources (also see the Patient Guide: A Guide for People Living with Osteoarthritis)

- Arthritis Today Supplement Guide (updated every 1–2 years)
- The Arthritis Foundation's Guide to Alternative Therapies. Horstman, J. (1999)
- Mayo Clinic on Chronic Pain, New York: Kensington. Swanson, DW, (1999).
- www.nccam.nih.gov (National Centre for Complementary & Alternative Medicine)
- http://dietary-supplements.info.nih.gov/ (Office of Dietary Supplements)
- www.mayoclinic.com
- www.canadian-health-network.ca
- www.quackwatch.org



GUIDELINES & PROTOCOLS



ADVISORY COMMITTEE

SUMMARY OF GUIDELINE

Effective Date: September 15, 2008

Osteoarthritis in Peripheral Joints – Diagnosis and Treatment

For full Guideline please go to website: http://www.BCGuidelines.ca

DIAGNOSIS

- OA is a clinical diagnosis
- Consider history, physical exam, exclusion of other diagnoses and impact of disease
- Early diagnosis is important for modifiable factors (weight loss, exercise programs and self-management)

INVESTIGATIONS

- No test is reliable for diagnosis
- X-rays may indicate OA, but may not relate to symptoms
- X-rays are generally not useful except for alternate diagnosis or orthopaedic referral
- When x-rays are necessary, specify they are for OA*
- Lab tests do not diagnose OA and are used mainly to monitor medications
- Joint aspirations may be used to rule out other conditions

MANAGEMENT

Patient education

- Explain OA as a chronic disease process
- Encourage self management & provide resources
- Encourage weight loss and diet plan if needed

Rehabilitation

- Recommend exercise programs (ROM, strengthening & aerobic) with joint protection
- Recommend assistive devices when needed

Medications

- There is no evidence that NSAIDs alter the natural course of arthritis. They provide symptom relief but are associated with some risks (GI & CV). Avoid long-term daily NSAID therapy
- Begin with monotherapy PRN and add/substitute medications depending on response and side effects
- Mild or moderate symptoms:
 - Acetaminophen max 4 g/day (lower dose where there is liver disease, alcohol abuse and for the elderly)
 - NSAIDS/Cox-2 inhibitors. Match adverse effects with patient history. Avoid long term daily use
 - Consider risks and benefits of gastroprotection
 - Joint aspiration and/or hyaluronic acid injections
 - Topicals (capsaicin or NSAIDs)
- Severe symptoms:
 - Use combination therapy as above and reassess
 - Intra-articular corticosteroid injections
 - In complex or difficult cases, consider referral to a rheumatologist for assistance with medication and analgesia titration, complex aspiration/injection procedures, and/or corticosteroid or hyaluronic acid injections

Indications for Referral:

- Internist or Rheumatologist for red flag conditions, complex/difficult cases, complications
- PT– for assessment and specific exercise recommendations
- OT– for assistive devices and home or work adaptations
- Dietician for weight management
- Orthopaedic Surgeon failure of non-operative program, increasing function restrictions, significant abnormal findings on exam, progression of disease on x-ray, considering use of opiates & intra-articular injections. The indications for arthroscopic knee surgery in patients with OA are similar to patients without arthritis.

Follow-up regularly and coordinate care

^{*} Indicate that the x-rays are for OA – For knees they must include standing AP, lateral, and skyline. For hip, specify OA hip series including lateral view of the affected hip and upper 1/3 of femur.

Osteoarthritis (OA) Medications Table

Effective Date: September 15, 2008

This Medication Table pertains to the Guideline *Osteoarthritis in Peripheral Joints – Diagnosis and Management* www.BCGuidelines.ca

Regularly review current listings of Health Canada advisories, warnings and recalls at: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/index_e.html

Non-Narcotic Aanalgesics – There is no strong evidence to support that oral NSAIDS differ from paracetamol/acetaminophen in pain relief* acetaminophen 650-1000 mg q4-6h OR SR caps 1300 mg q8h; max 4000 mg/day mefenamic acid√ 250 mg P0 q6h pm (generally 7 day max.) NSAIDs – Acetaminophen is the first choice. Trials have not demonstrated consistent superiority of one NSAID over another² acetylsalicylic acid (enteric-coated)√ (ibutoprofen√ 300-800 mg P0 tid-qid; max 2400 mg/day \$3-\$10 full naproxen√ 250-500 mg bid-tid max 1500 mg/day \$10-\$14 full diclofenac√ 50mg P0 bid-tid or 75mg bid; max 150 mg/day \$24-\$40 PC or full with SA epetodoxicity or renal impairment cardioxically are librariosistic max 200 mg/day \$16-\$32 PC or full with SA extensionally 25-50 mg p0 bid-tid; max 200 mg/day \$16-\$32 PC or full with SA extensionally 25-50 mg P0 bid-tid; max 200 mg/day \$16-\$32 PC or full with SA extensionally 25-50 mg P0 pd qd \$27-\$32 PC or full with SA extensionally 25-50 mg P0 pd qd \$21 PC or full with SA extensionally arrow dema blood dyscrasias thrombocytopenia erythema multiforme symptomic of aseptic menin sulindac√ 150-200 mg P0 qd \$22 PC or full with SA extensionally are dema blood dyscrasias thrombocytopenia erythema multiforme symptomic of aseptic menin sulindac√ 150-200 mg P0 bid; max 400 mg/day \$24-\$30 PC or full with SA extensionally are dema blood dyscrasias thrombocytopenia erythema multiforme symptomic of aseptic menin sulindac√ Either 300 mg bid or SR 600 mg od \$25-\$40 PC or full with SA extensionally are dema blood dyscrasias thrombocytopenia erythema multiforme symptomic of aseptic menin should be defined and the symptomic of sulindinated vision of fluid retention generics only for 300 mg tolmetin√ 200-600 mg P0 bid; max 1800 mg/day \$40-\$80 PC or full with SA extensionally are dema blood dyscrasias thrombocytopenia erythema multiforme bronchospasm, hepatotoxicity peptic ulcer, with without bronchospasm, hepatotoxicity peptic ulcer, with without	DRUG	DOSE	APPROX. COST/MONTH	PHARMACARE COVERAGE	SERIOUS SIDE EFFECTS
get; max 4000 mg/day mefenamic acid√ 250 mg P0 q6h prn (generally 7 day max.) Similar to NSAID risks below NSAIDs - Acetaminophen is the first choice. Trials have not demonstrated consistent superiority of one NSAID over another centeric-coatedy/ acetylsalicylic acid (enteric-coatedy/ ibuprofen√ 300-800 mg P0 tid-qid; max 2400 mg/day bibuprofen√ 300-800 mg P0 tid-qid; max 2400 mg/day s10-S14 full diclofenac√ 50mg P0 bid-tid or 75mg bid; max 150 mg/day diffunisal√ 250-500 mg bid-tid ror 75mg bid; max 150 mg/day diffunisal√ 550-500 mg P0 q12h s27-S32 PC or full with SA indomethacin√ 50mg P0 bid-tid; max 200 mg/day s16-S32 PC or full with SA indomethacin√ 55mg P0 bid or 50 mg P0 qid;max 300 mg/day s21 PC or full with SA meloxicam√ 7.5-15 mg P0 od s17-S20 PC or full with SA meloxicam√ 7.5-15 mg P0 dd or 50 mg P0 qid;max 300 mg/day s21 PC or full with SA meloxicam√ 7.5-15 mg P0 dd s22 PC or full with SA meloxicam√ 150-200 mg P0 bid; max 400 mg/day s22 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s22 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s22 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s24-S30 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s25-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s25-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 400 mg/day s25-5-40 PC or full with SA symptoms of aseptic menin sulindac√ 100-20-600 mg P0 bid; max 1800 mg/day s25-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s26-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s27-5-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s28-5-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s27-5-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s28-5-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s28-5-5-40 PC or full with SA sulindac√ 150-200 mg P0 bid; max 1800 mg/day s28-5-5-5-5-5-5-5-5-5-5-5-5-5-5-5-5-5-5-5	Non-Narcotic Aanalges	sics – There is no strong evidence to support that oral	NSAIDS differ from para	cetamol/acetaminophen in pair	n relief¹
NSAIDs - Acetaminophen is the first choice. Trials have not demonstrated consistent superiority of one NSAID over another? Similar of the professional profes	acetaminophen		\$5 - \$13	full for OA only via SA	rare elevations of INR when using warfarin anticoagulants, liver toxicity
acetylsalicylic acid centeric-coated \times \times \times 2600-5400 mg PO daily, divided q4-6h \$3-\$6 full apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class centeric since below apply to NSAID class of drugs centeric since below apply to NSAID class centeri	mefenamic acid√	250 mg PO q6h prn (generally 7 day max.)	\$0.34/tab		Similar to NSAID risks below
acetylsalicylic acid (enteric-coated)\ 2600-5400 mg PO daily, divided q4-6h (s1-coated)\ 300-800 mg PO tid-qid; max 2400 mg/day \$3-\$10 full may 1500 mg PO bid-tid max 1500 mg/day \$10-\$14 full esevere diarrhea hepatotoxicity severe diarrhea hepatotoxicity erand impairment 250-500 mg PO bid-tid max 1500 mg/day \$24-\$40 PC or full with SA hepatotoxicity erand impairment cardiovascular events flurbiprofem\ 50-100 mg PO bid-tid; max 300 mg/day \$16-\$32 PC or full with SA erand impairment cardiovascular events c	NSAIDs – Acetaminoph	nen is the first choice. Trials have not demonstrated c	onsistent superiority of o	ne NSAID over another ²	> The side-effects listed below
buprofen√ 300-800 mg P0 tid-qid; max 2400 mg/day \$3-\$10 full or without bleeding;		2600-5400 mg PO daily, divided q4-6h	\$3-\$6	full	apply to NSAID class of drugs:
hepatotoxicity	ibuprofen√	300-800 mg P0 tid-qid; max 2400 mg/day	\$3-\$10	full	or without bleeding;
didflunisal√ 250-500 mg P0 q12h	naproxen√	250-500 mg bid-tid max 1500 mg/day	\$10-\$14	full	
diffunisial √ 250-500 mg P0 q12h \$27-\$32 PC or full with SA • cardiovascular events CHF; angina; hypertension; arrhythmia; bronchospasm; pulmonary edema blood dyscrasias • cHF; angina; hypertension; arrhythmia; bronchospasm; pulmonary edema • blood dyscrasias • cHF; angina; hypertension; arrhythmia; bronchospasm; pulmonary edema • blood dyscrasias • blo	diclofenac√	50mg PO bid-tid or 75mg bid; max 150 mg/day	\$24-\$40	PC or full with SA	
indomethacin√ 25-50 mg bid-tid; max 200 mg/day \$5-\$15 PC or full with SA meloxicam√ 75 mg P0 tid or 50 mg P0 qid;max 300 mg/day \$21 PC or full with SA meloxicam√ 75.515 mg P0 od \$17-\$20 PC or full with SA nabumetone√ 500 mg \$30-\$60 PC or full with SA piroxicam√ 20 mg P0 qd \$22 PC or full with SA enthropyotypenia \$20 mg P0 pd \$24-\$30 PC or full with SA enthropyotypenia \$25-\$40 PC or full with SA enthropyotypenia \$25-\$40 PC or full with SA supptomsory dema \$25-\$40 PC or full with SA enthropyotypenia \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or aseptic mening blurder or diminished vision \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA supptoms or fluid retention \$25-\$40 PC or full with SA	diflunisal√	250-500 mg PO q12h	\$27-\$32	PC or full with SA	
ketoprofen√ 75 mg P0 tid or 50 mg P0 qid;max 300 mg/day \$21 PC or full with SA pulmonary edema meloxicam√ 7.5-15 mg P0 od \$17-\$20 PC or full with SA • blood dyscrasias nabumetone√ 500 mg \$30-\$60 PC or full with SA • blood dyscrasias piroxicam√ 20 mg P0 qd \$22 PC or full with SA • symptoms of aseptic menin sulindac√ 150-200 mg P0 bid; max 400 mg/day \$24-\$30 PC or full with SA • blurred or diminished vision tiaprofenic acid generics only for 300 mg PC or full with SA • blurred or diminished vision 10metin√ 200-600 mg P0 bid \$51 none GI bleed, erythema multiforme bronchospasm, hepatotoxicity bronchospasm, hepatotoxicity bronchospasm, hepatotoxicity ketorolac√ 10 mg P0 q4-6h; max 40 mg/day; short-term \$59 none peptic ulcer, with/without bleeding; fatalities in the elder Cox 2 inhibitors celecoxib 200 mg P0 od or 100 mg bid \$42 none; full with SA as above in NSAIDs NSAIDs & OtherTopicals diclofenac sodium 40 drops, applied qid \$50 none Allergic sk	flurbiprofen√	50-100 mg PO bid-tid; max 300 mg/day	\$16-\$32	PC or full with SA	CHF; angina; hypertension;
meloxicam√ 7.5-15 mg P0 od \$17-\$20 PC or full with SA blood dyscrasias • thrombocytopenia • symptoms of aseptic menin • symptoms of	indomethacin√	25-50 mg bid-tid; max 200 mg/day	\$5-\$15	PC or full with SA	arrhythmia; bronchospasm;
nabumetone√ 500 mg \$30-\$60 PC or full with SA erythema multiforme sulindac√ 150-200 mg P0 bid; max 400 mg/day \$22 PC or full with SA blurred or diminished vision blurred or diminished vision sulindac√ 150-200 mg P0 bid; max 400 mg/day \$24-\$30 PC or full with SA blurred or diminished vision sulindac√ Either 300 mg bid or SR 600 mg od \$25-\$40 PC or full with SA blurred or diminished vision sulfured or diminished vision sulfured profile with sa sulfured profile with s	ketoprofen√	75 mg PO tid or 50 mg PO qid;max 300 mg/day	\$21	PC or full with SA	
nabumetone√ 500 mg	meloxicam√	7.5-15 mg PO od	\$17-\$20	PC or full with SA	-
piroxicam√ 20 mg P0 qd \$22 PC or full with SA sulfindac√ 150-200 mg P0 bid; max 400 mg/day \$24-\$30 PC or full with SA blurred or diminished vision tiaprofenic acid generics only for 300 mg bid or SR 600 mg od \$25-\$40 PC or full with SA blurred or diminished vision fluid retention fluid retention fluid retention fluid retention fluid retention such as a subject of the policy of	nabumetone√	500 mg	\$30-\$60	PC or full with SA	, ,
tiaprofenic acid generics only for 300 mg tolmetin√ 200-600 mg P0 tid; max 1800 mg/day \$40-\$80 PC or full with SA etodolac 300 mg P0 bid \$51 none Gl bleed, erythema multiform bronchospasm, hepatotoxicity betorolac√ 10 mg P0 q4-6h; max 40 mg/day; short-term use only Cox 2 inhibitors celecoxib (no generics) NSAIDs & OtherTopicals diclofenac sodium 40 drops, applied qid \$50 none Colitis, arrhythmia, 1% may develop hepatitis menthol apply tid-qid ounopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full analysis, masking of infections	piroxicam√	20 mg PO qd	\$22	PC or full with SA	symptoms of aseptic meningitis
generics only for 300 mg tolmetin√ 200-600 mg P0 tid; max 1800 mg/day \$40-\$80 PC or full with SA etodolac 300 mg P0 bid \$51 none Gl bleed, erythema multiforme bronchospasm, hepatotoxicity betorolac√ 10 mg P0 q4-6h; max 40 mg/day; short-term use only peptic ulcer, with/without bleeding; fatalities in the elder Cox 2 inhibitors celecoxib (no generics) 200 mg P0 od or 100 mg bid \$42 none; full with SA as above in NSAIDs NSAIDs & OtherTopicals diclofenac sodium 40 drops, applied qid \$50 none colitis, arrhythmia, 1% may develop hepatitis menthol apply tid-qid \$7.40/50g tube none Allergic skin reaction capsaicin apply tid-qid to unopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	sulindac√	150-200 mg PO bid; max 400 mg/day	\$24-\$30	PC or full with SA	blurred or diminished vision
etodolac 300 mg PO bid \$51 none Gl bleed, erythema multiforme bronchospasm, hepatotoxicity bronchospasm, hepatotoxicity setorolac√ 10 mg PO q4-6h; max 40 mg/day; short-term use only \$59 none peptic ulcer, with/without bleeding; fatalities in the elder \$\frac{\colored{Cox 2 inhibitors}}{\colored{Cox 2 inhibitors}}\$\$\$ 200 mg PO od or 100 mg bid \$42 none; full with SA as above in NSAIDs \$\frac{\colored{NSAIDs & OtherTopicals}}{\colored{Colored{Cox 2 inhibitors}}\$\$\$\$ 0 none \$\frac{\colored{Colitis, arrhythmia, 1% may develop hepatitis}}{\colored{Colitis, arrhythmia, 1% may develop hepatitis}}\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	generics only for	Either 300 mg bid or SR 600 mg od	\$25-\$40	PC or full with SA	fluid retention
bronchospasm, hepatotoxicity ketorolac√ 10 mg PO q4-6h; max 40 mg/day; short-term use only	tolmetin√	200-600 mg PO tid; max 1800 mg/day	\$40-\$80	PC or full with SA	1
ketorolac√ 10 mg P0 q4-6h; max 40 mg/day; short-term use only \$59 none peptic ulcer, with/without bleeding; fatalities in the elder Cox 2 inhibitors celecoxib (no generics) 200 mg P0 od or 100 mg bid \$42 none; full with SA as above in NSAIDs NSAIDs & OtherTopicals diclofenac sodium 40 drops, applied qid \$50 none colitis, arrhythmia, 1% may develop hepatitis menthol apply tid-qid splut id-qid splut id-qid to unopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	etodolac	300 mg PO bid	\$51	none	Gl bleed, erythema multiforme,
celecoxib (no generics) NSAIDs & OtherTopicals diclofenac sodium 40 drops, applied qid \$50 none colitis, arrhythmia, 1% may develop hepatitis menthol apply tid-qid apply tid-qid to unopened skin capsaicin apply tid-qid to unopened skin serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior serior s	ketorolac√		\$59	none	
NSAIDs & OtherTopicals diclofenac sodium	Cox 2 inhibitors				
diclofenac sodium 40 drops, applied qid \$50 none colitis, arrhythmia, 1% may develop hepatitis menthol apply tid-qid \$7.40/50g tube none Allergic skin reaction capsaicin apply tid-qid to unopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections		200 mg PO od or 100 mg bid	\$42	none; full with SA	as above in NSAIDs
develop hepatitis menthol apply tid-qid \$7.40/50g tube none Allergic skin reaction capsaicin apply tid-qid to unopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	NSAIDs & OtherTopical	Is			
capsaicin apply tid-qid to unopened skin \$20-\$40 none Skin irritation; sun sensitivity Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	diclofenac sodium	40 drops, applied qid	\$50	none	
Intra-Articular Medications (injection): steroids triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	menthol	apply tid-qid	\$7.40/50g tube	none	Allergic skin reaction
triamcinolone 2.5-40 mg intra-articularly \$2.60-\$5.50 per injection full anaphylaxis, masking of infections	capsaicin	apply tid-qid to unopened skin	\$20-\$40	none	Skin irritation; sun sensitivity
injection infections	Intra-Articular Medica	ations (injection): steroids			
Viscosumplementation (Devices as nor Health Canada)	triamcinolone	2.5-40 mg intra-articularly		full	
viscosupplicitication (bevices as per nearth bandua)	Viscosupplementation	(Devices as per Health Canada)			
hyaluronic acid 1-3 injections \$200-\$400 per vial none allergic reaction	hyaluronic acid	1-3 injections	\$200-\$400 per vial	none	allergic reaction

[√] Generics available

Pharmacare coverage: full= full coverage, PC=partial coverage, SA=special authority, none=no coverage

Note: Cardiovascular risk with NSAIDS and Cox-2 inhibitors and GI risk with NSAIDs*

- *References presented in full guideline
- 1. Tanna, S. Osteoarthritis opportunities to address pharmaceutical gaps. 2004. Available at URL: http://mednet3.who.int/pri oritymeds/report/background/osteoarthritis.doc. Accessed October 30, 2008.
- 2. The University of British Columbia Therapeutics Initiative. Should we be using NSAIDS for the treatment of Osteoarthritis and "Rheumatism". Therapeutics Letter 1995;4:1-4. Available at URL: http://www.ti.ubc.ca/PDF/4.PDF. Accessed October 30, 2008.

^{*}Special Authority criteria and forms are available on the PharmaCare Web site at http://www.health.gov.bc.ca/pharme/sa/criteria/formsindex.html

77

Height (metres)	1.47	1.5	1.53	1.56	1.59	1.62	1.65	1.68	1.71	1.74	1.77	1.8	1.83	1.86	1.89	1.92	1.95		
136	63	60	58	56	54	52	50	48	47	45	43	42	41	39	38	37	36	300	9
134	62	60	57	55	53	51	49	47	46	44	43	41	40	39	38	36	35	295	0BESE
132	61	59	56	54	52	50	48	47	45	44	42	41	39	38	37	36	35	291	IV
130	60	58	56	53	51	50	48	46	44	43	41	40	39	38	36	35	34	287	30 (includes
128	59	57	55	53	51	49	47	45	44	42	41	40	38	37	36	35	34	282	inclu
126	58	56	54	52	50	48	46	45	43	42	40	39	38	36	35	34	33	278	səbı
124	57	55	53	51	49	47	46	44	42	41	40	38	37	36	35	34	33	273	Class
122	56	54	52	50	48	46	45	43	42	40	39	38	36	35	34	33	32	269	ass l
120	56	53	51	49	47	46	44	43	41	40	38	37	36	35	34	33	32	265	<u>, </u>
118	55	52	50	48	47	45	43	42	40	39	38	36	35	34	33	32	31	260	≡
116	54	52	50	48	46	44	43	41	40	38	37	36	35	34	32	31	31	256	
114	53	51	49	47	45	43	42	40	39	38	36	35	34	33	32	31	30	251	
112	52	50	48	46	44	43	41	40	38	37	36	35	33	32	31	30	29	247	9
110	51	49	47	45	44	42	40	39	38	36	35	34	33	32	31	30	29	243	R.
108	50	48	46	44	43	41	40	38	37	36	34	33	32	31	30	29	28	238	OVERWEIGHT 25.0 -
106	49	47	45	44	42	40	39	38	36	35	34	33	32	31	30	29	28	234	꿐
104	48	46	44	43	41	40	38	37	36	34	33	32	31	30	29	28	27	229	25.
102	47	45	44	42	40	39	37	36	35	34	33	31	30	29	29	28	27	225	
100	46	44	43	41	40	38	37	35	34	33	32	31	30	29	28	27	26	220	29.9
Weight (kilograms) 88 88 88 88	45	44	42	40	39	37	36	35	34	32	31	30	29	28	27	27	26	216	9
96 az	44	43	41	39	38	37	35	34	33	32	31	30	29	28	27	26	25	212	
94	44	42	40	39	37	36	35	33	32	31	30	29	28	27	26	25	25	207	
¥ 92	43	41	39	38	36	35	34	33	31	30	29	28	27	27	26	25	24	203 198 194	
6ig h	42	40 39	38 38	37	36 25	34	33	32 31	31	30 29	29 28	28 27	27 26	26 25	25 25	24 24	24 23		N
≫ °° 86	40	38	30 37	36 35	35 34	34 33	32 32	30	30 29	29 28	20 27	27	26	25 25	24	23	23 23	194	RM/
84	39	37	36	35	33	32	31	30	29	28	27	26	25	24	24	23	23 22	185	NORMAL 18.5
82	38	36	35	34	32	31	30	29	28	27	26	25	24	24	23	22	22	181	8.5
80	37	36	34	33	32	30	29	28	27	26	26	25	24	23	22	22	21	176	- 2
78	36	35	33	32	31	30	29	28	27	26	25	24	23	23	22	21	21	172	24.9
76	35	34	32	31	30		28	27	26	25		23	23	22	21	21	20	168	
74	34	33	32	30 [29	28	27	26	25	24	24	23	22	21	21	20	19	163	
72	33	32	31	30	28	27	26	26	25	24	23	22	21	21	20	20	19	159	
70	32	31	30 [29	28	27	26	25	24	23	22	22	21	20	20	19	18	154	
68	31	30	29	28	27	26	25	24	23	22	22	21	20	20	19	18	18	150	\subseteq
66	31 Г	29	1 28	27	26	25	24	23	23	22	21	20	20	19	18	18	17	146	UNDERWEIGHT <
64	30	28	27	26	25	24	24	23	22	21	20	20	19	18	18	17	17	141	₩.
62	29	28	26	25	25	24	23	22	21	20	20	19	19	18	17	17	16	137	Ë
60	28	27	26	25	24	23	22	21	21	20	19	19	18	17	17	16	16	132	
58	27	26	25	24	23	22	21	21	20	19	19	18	17	17	16	16	15	128	18.5
56	26	25	24	23	22	21	21	20	19	18	18	17	17	16	16	15	15	123	O1
54	25	24	23	22	21	21	20	19	18	18	17	17	16	16	15	15	14	119	
52	24	23	22	21	21	20	19	18	18	17	17	16	16	15	15	14	14	115	
50	23	22	21	21	20	19	18	18	17	17	16	15	15	14	14	14	13	110	
48	22	21	21	20	19	18	18	17	16	16	15	15	14	14	13	13	13	106	
46	21	20	20	19	18	18	17	16	16	15	15	14	14	13	13	12	12	101	

Height (inches) 58 59 60 61 63 64 65 66 67 69 70 71 72 73 74 76